TY - JOUR
T1 - Psychosocial outcomes in patients with recurrent major depressive disorder during 2 years of maintenance treatment with venlafaxine extended release
AU - Trivedi, Madhukar H.
AU - Dunner, David L.
AU - Kornstein, Susan G.
AU - Thase, Michael E.
AU - Zajecka, John M.
AU - Rothschild, Anthony J.
AU - Friedman, Edward S.
AU - Shelton, Richard C.
AU - Keller, Martin B.
AU - Kocsis, James H.
AU - Gelenberg, Alan
N1 - Funding Information:
Dr. Thase has provided scientific consultation to AstraZeneca, Bristol-Myers Squibb, Cephalon, Cyberonics, Eli Lilly, Forest, GlaxoSmithKline, Janssen, MedAvante, Neuronetics, Novartis, Schering-Plough, Sepracor, Shire, Supernus, Takeda, Transcept, and Wyeth-Ayerst. He has been on the speaker's bureau for AstraZeneca, Bristol-Myers Squibb, Cyberonics, Eli Lilly, GlaxoSmithKline, Schering-Plough (formerly Organon), sanofi-aventis, and Wyeth-Ayerst. He receives grant funding from Eli Lilly, GlaxoSmithKline, the National Institute of Mental Health, and Sepracor. He has equity holdings in MedAvante and receives royalties from American Psychiatric Association Publishing, Guilford Press, Herold House, Oxford University Press, and WW Norton & Company. He has provided expert testimony for Jones Day and Philips Lyttle LLP and Pepper Hamilton LLP. His wife is employed as a senior medical director for Embryon, LLC (formerly Medesta Publications Group, A Business of Advogent).
Funding Information:
Dr. Kocsis has received grants from the National Institute of Mental Health, the National Institute on Drug Abuse, the Burroughs Wellcome Trust, Pritzker Consortium, AstraZeneca, sanofi-aventis, Forest, Novartis, CNS Response, and Roche. He has served on the speaker's bureau for Pfizer, Wyeth, and AstraZeneca and on advisory boards for Pfizer and Wyeth.
Funding Information:
Dr. Shelton has received grants from the National Institute of Mental Health, Bristol-Myers Squibb, Eli Lilly, Forest, Janssen, Novartis, Otsuka, PamLab, Pfizer, Repligen, AstraZeneca, Cyberonics, GlaxoSmithKline, and Wyeth. He has been a consultant or served on advisory boards for the National Institute of Mental Health, Best Practice Project Management Inc, Forest, Janssen, Novartis, Otsuka, PamLab, Repligen, EVOTEC AG, AstraZeneca, Cyberonics, GlaxoSmithKline, and Wyeth. Dr. Shelton has been on the speaker's bureau for AstraZeneca, Best Practice Project Management Inc, Cyberonics, Eli Lilly, Forest, GlaxoSmithKline, Janssen, Novartis, Otsuka, PamLab, Repligen, and Wyeth.
Funding Information:
Dr. Friedman has provided scientific consultation to Cephalon, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Wyeth, and Pfizer. He has been on the speaker's bureau for Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Forest, GlaxoSmithKline, Pfizer, Pharmacia & Upjohn, Roerig Division of Pfizer, and Wyeth. Dr. Friedman has received grants from AstraZeneca, Bristol-Myers Squibb, Cyberonics, Eli Lilly, Forest, GlaxoSmithKline, Northstar, Novartis, Organon, Pharmacia & Upjohn, Pfizer, sanofi-aventis, and Wyeth. He owns stock in Cephalon and has received other financial or material support from Abbott (expert testimony, patents, royalties).
Funding Information:
Dr. Rothschild has been a consultant for Eli Lilly, Forest, GlaxoSmithKline, and Takeda and has received research grants from the National Institute of Mental Health, Cyberonics, and Wyeth. He has received royalties from the Rothschild Scale for Antidepressant Tachyphylaxis and American Psychiatric Press.
Funding Information:
Dr. Dunner has received grant support from Eli Lilly, Pfizer, GlaxoSmithKline, Wyeth, Bristol-Myers Squibb, Forest, Cyberonics, Janssen, and Novartis. He has been a consultant or on the advisory board of Eli Lilly, Pfizer, GlaxoSmithKline, Wyeth, Bristol-Myers Squibb, Forest, Cyberonics, Roche Diagnostics, Cypress, Corcept, Janssen, Novartis, Shire, Somerset, Otsuka Healthcare Technology Systems, and Jazz Pharmaceuticals. He has been on the speaker's bureau for Eli Lilly, Pfizer, GlaxoSmithKline, Wyeth, Bristol-Myers Squibb, Organon, Jazz Pharmaceuticals, and AstraZeneca. Dr. Dunner also owns a NeuroStar device (Neuronetics) for treating patients with rTMS.
Funding Information:
Funding for this study was provided by Wyeth which was acquired by Pfizer Inc in October 2009. Wyeth Research was involved in designing the study, collecting, analyzing, and interpreting data, and the decision to submit this manuscript for publication.
PY - 2010/11
Y1 - 2010/11
N2 - Background: Psychosocial outcomes from the Prevention of Recurrent Episodes of Depression with Venlafaxine ER for Two Years (PREVENT) study were evaluated. Methods: Adult outpatients with recurrent major depressive disorder (MDD) and response or remission following 6-month continuation treatment with venlafaxine extended release (ER) were randomized to receive venlafaxine ER or placebo for 1 year. Patients without recurrence on venlafaxine ER during year 1 were randomized to venlafaxine ER or placebo for year 2. Psychosocial functioning was assessed using the Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q), Life Enjoyment Scale-Short Version (LES-S), Social Adjustment Scale-Self-Report (SAS-SR) total and individual factors, Short Form Health Survey (SF-36) (vitality, social functioning, and role function-emotional items), and Longitudinal Interval Follow-up Evaluation (LIFE). Results: At year 1 end, better overall psychosocial functioning was seen among patients randomly assigned to venlafaxine ER (n = 129) vs placebo (n = 129), with significant differences at end point on SF-36 role function-emotional, Q-LES-Q, and SAS-SR total, and work, house work, social/leisure, and extended-family factor scores (p ≤ 0.05). At year 2 end, significant differences favored venlafaxine ER (n = 43) vs placebo (n = 40) on SF-36 vitality and role function-emotional, Q-LES-Q, LES-S, LIFE, and SAS-SR total, social/leisure, and extended-family factor scores (p ≤ 0.05). Limitations: Patients with chronic MDD or treatment resistance were excluded and long-term specialist care was a financial incentive for treatment compliance. Discontinuation-related adverse events may have compromised the integrity of the treatment blind. Conclusions: For patients with recurrent MDD, 2 years' maintenance therapy with venlafaxine ER may improve psychosocial functioning vs placebo.
AB - Background: Psychosocial outcomes from the Prevention of Recurrent Episodes of Depression with Venlafaxine ER for Two Years (PREVENT) study were evaluated. Methods: Adult outpatients with recurrent major depressive disorder (MDD) and response or remission following 6-month continuation treatment with venlafaxine extended release (ER) were randomized to receive venlafaxine ER or placebo for 1 year. Patients without recurrence on venlafaxine ER during year 1 were randomized to venlafaxine ER or placebo for year 2. Psychosocial functioning was assessed using the Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q), Life Enjoyment Scale-Short Version (LES-S), Social Adjustment Scale-Self-Report (SAS-SR) total and individual factors, Short Form Health Survey (SF-36) (vitality, social functioning, and role function-emotional items), and Longitudinal Interval Follow-up Evaluation (LIFE). Results: At year 1 end, better overall psychosocial functioning was seen among patients randomly assigned to venlafaxine ER (n = 129) vs placebo (n = 129), with significant differences at end point on SF-36 role function-emotional, Q-LES-Q, and SAS-SR total, and work, house work, social/leisure, and extended-family factor scores (p ≤ 0.05). At year 2 end, significant differences favored venlafaxine ER (n = 43) vs placebo (n = 40) on SF-36 vitality and role function-emotional, Q-LES-Q, LES-S, LIFE, and SAS-SR total, social/leisure, and extended-family factor scores (p ≤ 0.05). Limitations: Patients with chronic MDD or treatment resistance were excluded and long-term specialist care was a financial incentive for treatment compliance. Discontinuation-related adverse events may have compromised the integrity of the treatment blind. Conclusions: For patients with recurrent MDD, 2 years' maintenance therapy with venlafaxine ER may improve psychosocial functioning vs placebo.
KW - Maintenance treatment
KW - Major depressive disorder
KW - Psychosocial outcomes
KW - Venlafaxine extended release
UR - http://www.scopus.com/inward/record.url?scp=77957347521&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77957347521&partnerID=8YFLogxK
U2 - 10.1016/j.jad.2010.04.011
DO - 10.1016/j.jad.2010.04.011
M3 - Article
C2 - 20510459
AN - SCOPUS:77957347521
SN - 0165-0327
VL - 126
SP - 420
EP - 429
JO - Journal of Affective Disorders
JF - Journal of Affective Disorders
IS - 3
ER -